CoChat
Sign Up
Cited by 47

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant

Zhang, Na-Na, Zhang, Rong-Rong, Zhang, Yi-Fei, Ji, Kai, Xiong, Xiao-Chuan, Qin, Qian-Shan, Gao, Peng, Lu, Xi-Shan, Zhou, Hang-Yu, Song, Hai-Feng, Ying, Bo, Qin, Cheng-Feng·2022·Cell Research
DOI 10.1038/s41422-022-00626-wPMC PMC8853430
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-022-00626-w

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development and characterization of an updated RBD-based mRNA vaccine against Omicron. a Structural model of amino acid mutations in the Spike protein of the Omicron variant of SARS-CoV-2. The model was built using SWISS-MODEL15 with a structure of SARS-CoV-2 spike protein (PDB: 6 ZGE16) as the template model and visualized with PyMOL(v2.5.0). The RBD, NTD, and S2 region of Spike protein were colored by red, blue and green, respectively. All mutations in the RBD were highlighted in darker color, and mutations or deletions in other region of Spike protein were colored in gray. b The 50% neutralization titer of sera from ARCoV vaccinees (n = 11) were analyzed using VSV-based pseudovirus for WT and Omicron, respectively. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using unpaired t-test (***P < 0.001). c Neutralization assay after a booster ARCoV vaccination in mice. Groups of 8–9-month female BALB/c mice were intramuscularly immunized and boosted with 10 μg ARCoV (n = 3), and sera were detected at the indicated time points. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using a one-way ANOVA with multiple comparisons tests (n.s., not significant). d Schematic representation of the mRNA construct encoding Omicron RBD. The mutation sites were indicated with red lines. e Omicron RBD protein expression from mRNA in Huh-7 cells. Cells were transfected with Omicron RBD-encoding mRNAs, and the supernatants was detected by Western blotting assay 24 h after transfection. f In vivo expression of ARCoV-Omicron in mice. Groups of 6–8-week female ICR mice (n = 5) were intravenously inoculated with ARCoV-Omicron, and PBS (n = 4) was used as Placebo. The serum concentration of Omicron RBD was measured by ELISA. Data are shown as means ± SEM and analyzed using one-way ANOVA with multiple comparisons tests (n.s., not significant; ***P < 0.001). g, h The immunogenicity of ARCoV-Omicron in mice. Groups of 6–8-week female ICR mice (n = 5) were immunized intramuscularly with two doses of 10 μg of ARCoV-Omicron at 7-day interval. Sera were collected at 14 days after initial immunization and subjected to IgG and neutralization antibody assays. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using a one-way ANOVA with multiple comparisons tests (**P < 0.01, ***P < 0.001). i Timeline for the rapid development of ARCoV-Omicron mRNA vaccine.
Fig. 1 Development and characterization of an updated RBD-based mRNA vaccine against Omicron. a Structural model of amino acid mutations in the Spike protein of the Omicron variant of SARS-CoV-2. The model was built using SWISS-MODEL15 with a structure of SARS-CoV-2 spike protein (PDB: 6 ZGE16) as the template model and visualized with PyMOL(v2.5.0). The RBD, NTD, and S2 region of Spike protein were colored by red, blue and green, respectively. All mutations in the RBD were highlighted in darker color, and mutations or deletions in other region of Spike protein were colored in gray. b The 50% neutralization titer of sera from ARCoV vaccinees (n = 11) were analyzed using VSV-based pseudovirus for WT and Omicron, respectively. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using unpaired t-test (***P < 0.001). c Neutralization assay after a booster ARCoV vaccination in mice. Groups of 8–9-month female BALB/c mice were intramuscularly immunized and boosted with 10 μg ARCoV (n = 3), and sera were detected at the indicated time points. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using a one-way ANOVA with multiple comparisons tests (n.s., not significant). d Schematic representation of the mRNA construct encoding Omicron RBD. The mutation sites were indicated with red lines. e Omicron RBD protein expression from mRNA in Huh-7 cells. Cells were transfected with Omicron RBD-encoding mRNAs, and the supernatants was detected by Western blotting assay 24 h after transfection. f In vivo expression of ARCoV-Omicron in mice. Groups of 6–8-week female ICR mice (n = 5) were intravenously inoculated with ARCoV-Omicron, and PBS (n = 4) was used as Placebo. The serum concentration of Omicron RBD was measured by ELISA. Data are shown as means ± SEM and analyzed using one-way ANOVA with multiple comparisons tests (n.s., not significant; ***P < 0.001). g, h The immunogenicity of ARCoV-Omicron in mice. Groups of 6–8-week female ICR mice (n = 5) were immunized intramuscularly with two doses of 10 μg of ARCoV-Omicron at 7-day interval. Sera were collected at 14 days after initial immunization and subjected to IgG and neutralization antibody assays. The red dashed lines indicate the detection limit of the assay. Data are shown as means ± SEM and analyzed using a one-way ANOVA with multiple comparisons tests (**P < 0.01, ***P < 0.001). i Timeline for the rapid development of ARCoV-Omicron mRNA vaccine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 11

  1. Plante, J. A. et al. Cell Host Microbe 29, 508–515 (2021). · DOI · Paper page
  2. He, X., Hong, W., Pan, X., Lu, G. & Wei, X. Med. Commun. 2, 838–845 (2021).
  3. Cao, Y. et al. Nature https://doi.org/10.1038/d41586-021-03796-6 (2021). · DOI
  4. Planas, D. et al. Nature https://doi.org/10.1038/d41586-021-03827-2 (2021). · DOI
  5. Liu, L. et al. Nature https://doi.org/10.1038/d41586-021-03826-3 (2021). · DOI · Paper page
  6. Cele, S. et al. Nature https://doi.org/10.1038/d41586-021-03824-5 (2021). · DOI
  7. Cameroni, E. et al. Nature https://doi.org/10.1038/d41586-021-03825-4 (2021). · DOI
  8. Saciuk, Y., Kertes, J., Shamir Stein, N. & Ekka Zohar, A. J. Infect. Dis. 225, 30–33 (2022). · DOI
  9. Ai, J. et al. Cell Res. 32, 103–106 (2022). · DOI
  10. Corbett, K.S. et al. bioRxiv, https://doi.org/10.1101/2021.08.11.456015 (2021). · DOI
  11. Waterhouse, A. et al. Nucleic Acids Res. 46, W296–W303 (2018). · DOI

Cited by

Sorted by citations

See all 47

Metadata

Authors
Zhang, N.-N., Zhang, R.-R., Zhang, Y.-F., Ji, K., Xiong, X.-C., Qin, Q.-S., Gao, P., Lu, X.-S., Zhou, H.-Y., Song, H.-F., Ying, B., & Qin, C.-F.
ORCID
Qin, Cheng-Feng
Venue
Cell Research
Publisher
Springer Science and Business Media LLC
Published
2022-02-14
Volume
32
Issue
4
Pages
401-403
ISSN
  • 1001-0602
  • 1748-7838
DOI
10.1038/s41422-022-00626-w
PMC
PMC8853430
Cited by
47
References
5
Language
en
Licence
Funders
National Natural Science Foundation of China (32000663)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. https://app.cochat.ai/papers/10.1038/s41422-022-00626-w
The paper
Zhang, N.-N., Zhang, R.-R., Zhang, Y.-F., Ji, K., Xiong, X.-C., Qin, Q.-S., Gao, P., Lu, X.-S., Zhou, H.-Y., Song, H.-F., Ying, B., & Qin, C.-F. (2022). Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. Cell Research. https://doi.org/10.1038/s41422-022-00626-w